Challenges in monoclonal antibody-based therapies

Area of Science:

• Biotechnology
• Immunotherapy
• Molecular Biology

Background:

• Therapeutic monoclonal antibodies (mAbs) are a rapidly expanding class of drugs for treating inflammatory diseases and cancer.
• Current manufacturing processes for mAbs face limitations in production capacity and high costs.
• Existing administration methods, such as repeated high-dose injections, can lead to side effects.

Purpose of the Study:

• To explore the potential of in vivo production of therapeutic monoclonal antibodies (mAbs) as an alternative to traditional manufacturing.
• To review the advantages of in vivo gene delivery for therapeutic antibodies, including improved efficacy and reduced costs.
• To discuss the challenges and prospects of genetic in vivo delivery for antibody-based immunotherapies.

Main Methods:

• Review of current antibody-based immunotherapies and their limitations.
• Analysis of genetic in vivo delivery strategies for therapeutic antibody production.
• Discussion of three primary approaches for stable, long-term in vivo antibody expression: integrating vectors, ex vivo cell modification, and encapsulated cell implantation.

Main Results:

• In vivo production can maintain stable, non-toxic therapeutic antibody levels, avoiding repeated injections and associated side effects.
• Genetic delivery significantly reduces the high manufacturing and purification costs associated with conventional antibody production.
• In vivo/ex vivo mAb gene transfer presents an economically viable and attractive therapeutic option.

Conclusions:

• Genetic in vivo delivery of therapeutic monoclonal antibodies (mAbs) offers a viable solution to current manufacturing challenges.
• This approach promises enhanced therapeutic efficacy, improved patient safety, and reduced treatment costs.
• Further research into integrating vectors, ex vivo cell modification, and encapsulated cell strategies is crucial for advancing in vivo antibody therapies.